{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:04:19Z","timestamp":1789736659875,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Centro Ames","award":["Centro Ames"],"award-info":[{"award-number":["Centro Ames"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07273-w","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:38:15Z","timestamp":1762342695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations"],"prefix":"10.1186","volume":"23","author":[{"given":"Monica","family":"Ianniello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ottaiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Santorsola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sirica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Picone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Ciappina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia Maria","family":"Cossu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Circelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sabbatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Sperlongano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Berretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"1","key":"7273_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41575-023-00841-9","volume":"21","author":"CC Murphy","year":"2024","unstructured":"Murphy CC, Zaki TA. Changing epidemiology of colorectal cancer - birth cohort effects and emerging risk factors. Nat Rev Gastroenterol Hepatol. 2024;21(1):25\u201334. https:\/\/doi.org\/10.1038\/s41575-023-00841-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"7273_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1568009617666170209095143","volume":"18","author":"A Nappi","year":"2018","unstructured":"Nappi A, Berretta M, Romano C, Tafuto S, Cassata A, Casaretti R, Silvestro L, Divitiis C, Alessandrini L, Fiorica F, Ottaiano A, Nasti G. Metastatic colorectal cancer: role of target therapies and future perspectives. Curr Cancer Drug Targets. 2018;18(5):421\u20139. https:\/\/doi.org\/10.2174\/1568009617666170209095143.","journal-title":"Curr Cancer Drug Targets"},{"issue":"10449","key":"7273_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","volume":"404","author":"C Eng","year":"2024","unstructured":"Eng C, Yoshino T, Ru\u00edz-Garc\u00eda E, Mostafa N, Cann CG, O\u2019Brian B, Benny A, Perez RO, Cremolini C. Colorectal cancer. Lancet. 2024;404(10449):294\u2013310. https:\/\/doi.org\/10.1016\/S0140-6736(24)00360-X.","journal-title":"Lancet"},{"issue":"7","key":"7273_CR4","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3390\/cancers12071919","volume":"12","author":"A Ottaiano","year":"2020","unstructured":"Ottaiano A, Normanno N, Facchini S, Cassata A, Nappi A, Romano C, Silvestro L, De Stefano A, Rachiglio AM, Roma C, Maiello MR, Scala S, Delrio P, Tatangelo F, Di Mauro A, Botti G, Avallone A, Nasti G. Study of Ras mutations\u2019 prognostic value in metastaticcolorectal cancer: STORIA analysis. Cancers (Basel). 2020;12(7):1919. https:\/\/doi.org\/10.3390\/cancers12071919.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"7273_CR5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s10555-020-09912-8","volume":"39","author":"T Tak\u00e1cs","year":"2020","unstructured":"Tak\u00e1cs T, Kudlik G, Kurilla A, Szeder B, Buday L, Vas V. The effects of mutant Ras proteins on the cell signalome. Cancer Metastasis Rev. 2020;39(4):1051\u201365. https:\/\/doi.org\/10.1007\/s10555-020-09912-8.","journal-title":"Cancer Metastasis Rev"},{"issue":"14","key":"7273_CR6","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Cancer Res. 2020;80(14):2969\u201374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3682.","journal-title":"Cancer Res"},{"issue":"8","key":"7273_CR7","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s10147-020-01691-0","volume":"25","author":"T Yamada","year":"2020","unstructured":"Yamada T, Matsuda A, Takahashi G, Iwai T, Takeda K, Ueda K, Kuriyama S, Koizumi M, Shinji S, Yokoyama Y, Ohta R, Yoshida H. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy. Int J Clin Oncol. 2020;25(8):1523\u201332. https:\/\/doi.org\/10.1007\/s10147-020-01691-0.","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"7273_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41417-020-0174-y","volume":"27","author":"K Choucair","year":"2020","unstructured":"Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther. 2020;27(12):841\u201353. https:\/\/doi.org\/10.1038\/s41417-020-0174-y.","journal-title":"Cancer Gene Ther"},{"key":"7273_CR9","doi-asserted-by":"publisher","first-page":"689076","DOI":"10.3389\/fimmu.2021.689076","volume":"12","author":"XL Zou","year":"2021","unstructured":"Zou XL, Li XB, Ke H, Zhang GY, Tang Q, Yuan J, Zhou CJ, Zhang JL, Zhang R, Chen WY. Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer. Front Immunol. 2021;12:689076. https:\/\/doi.org\/10.3389\/fimmu.2021.689076.","journal-title":"Front Immunol"},{"issue":"5","key":"7273_CR10","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.3390\/ijms23052594","volume":"23","author":"M Okada","year":"2022","unstructured":"Okada M, Shimizu K, Fujii SI. Identification of neoantigens in cancer cells as targets for immunotherapy. Int J Mol Sci. 2022;23(5):2594. https:\/\/doi.org\/10.3390\/ijms23052594.","journal-title":"Int J Mol Sci"},{"key":"7273_CR11","doi-asserted-by":"publisher","first-page":"104342","DOI":"10.1016\/j.critrevonc.2024.104342","volume":"197","author":"A Marques","year":"2024","unstructured":"Marques A, Cavaco P, Torre C, Sepodes B, Rocha J. Tumor mutational burden in colorectal cancer: implications for treatment. Crit Rev Oncol Hematol. 2024;197:104342. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104342.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"17","key":"7273_CR12","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, Philip R, Ghosh S, Theoret MR, Beaver JA, Pazdur R, Lemery SJ. FDA approval summary: pembrolizumab for the treatment of tumor mutational Burden-High solid tumors. Clin Cancer Res. 2021;27(17):4685\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0327.","journal-title":"Clin Cancer Res"},{"key":"7273_CR13","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386\u2013422. https:\/\/doi.org\/10.1093\/annonc\/mdw235.","journal-title":"Ann Oncol"},{"key":"7273_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1200\/JCO.2014.56.1894","volume":"33","author":"L Martin","year":"2015","unstructured":"Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015;33:90\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.56.1894.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7273_CR15","doi-asserted-by":"publisher","first-page":"100145","DOI":"10.1016\/j.esmoop.2021.100145","volume":"6","author":"A Trullas","year":"2021","unstructured":"Trullas A, Delgado J, Genazzani A, Mueller-Berghaus J, Migali C, M\u00fcller-Egert S, Zander H, Enzmann H, Pignatti F. The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. ESMO Open. 2021;6(3):100145. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100145.","journal-title":"ESMO Open"},{"key":"7273_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"7273_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2.","journal-title":"Genome Med"},{"key":"7273_CR18","doi-asserted-by":"publisher","first-page":"15180","DOI":"10.1038\/ncomms15180","volume":"8","author":"I Cortes-Ciriano","year":"2017","unstructured":"Cortes-Ciriano I, Lee S, Park WY, Kim TM, Park PJ. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun. 2017;8:15180. https:\/\/doi.org\/10.1038\/ncomms15180.","journal-title":"Nat Commun"},{"key":"7273_CR19","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler Transorfm. Bioinformatics. 2009;25:1754\u201360. https:\/\/doi.org\/10.1093\/bioinformatics\/btp324.","journal-title":"Bioinformatics"},{"issue":"1","key":"7273_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of American pathologists. J Mol Diagn. 2017;19(1):4\u201323. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.10.002.","journal-title":"J Mol Diagn"},{"issue":"2","key":"7273_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jmoldx.2022.11.002","volume":"25","author":"MM Li","year":"2023","unstructured":"Li MM, Cottrell CE, Pullambhatla M, Roy S, Temple-Smolkin RL, Turner SA, Wang K, Zhou Y, Vnencak-Jones CL. Assessments of somatic variant classification using the association for molecular pathology\/American society of clinical Oncology\/College of American pathologists guidelines: A report from the association for molecular pathology. J Mol Diagn. 2023;25(2):69\u201386. https:\/\/doi.org\/10.1016\/j.jmoldx.2022.11.002.","journal-title":"J Mol Diagn"},{"issue":"1","key":"7273_CR22","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.esmoop.2021.100336","volume":"7","author":"M Palmeri","year":"2022","unstructured":"Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P, Riedlinger G, Stephenson R, de Meritens AB, Leiser A, Mayer T, Chan N, Spencer K, Girda E, Malhotra J, Chan T, Subbiah V, Groisberg R. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022;7(1):100336. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100336.","journal-title":"ESMO Open"},{"issue":"9","key":"7273_CR23","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/nmeth.3484","volume":"12","author":"H Yang","year":"2015","unstructured":"Yang H, Robinson PN, Wang K. Phenolyzer: phenotype-based prioritization of candidate genes for human diseases. Nat Methods. 2015;12(9):841\u20133. https:\/\/doi.org\/10.1038\/nmeth.3484.","journal-title":"Nat Methods"},{"issue":"2","key":"7273_CR24","doi-asserted-by":"publisher","first-page":"e007800","DOI":"10.1136\/jitc-2023-007800","volume":"12","author":"R Esposito Abate","year":"2024","unstructured":"Esposito Abate R, Pasquale R, Sacco A, Simeon V, Maiello MR, Frezzetti D, Chiodini P, Normanno N. Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN path initiative. J Immunother Cancer. 2024;12(2):e007800. https:\/\/doi.org\/10.1136\/jitc-2023-007800.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"7273_CR25","doi-asserted-by":"publisher","first-page":"e001904","DOI":"10.1136\/jitc-2020-001904","volume":"9","author":"J Ramos-Paradas","year":"2021","unstructured":"Ramos-Paradas J, Hern\u00e1ndez-Prieto S, Lora D, Sanchez E, Rosado A, Caniego-Casas T, Carrizo N, Enguita AB, Mu\u00f1oz-Jimenez MT, Rodriguez B, Perez-Gonzalez U, G\u00f3mez-S\u00e1nchez D, Ferrer I, Ponce Aix S, Nu\u00f1ezBuiza \u00c1, Garrido P, Palacios J, Lopez-Rios F, Garrido-Martin EM, Paz-Ares L. Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels. J Immunother Cancer. 2021;9(5):e001904. https:\/\/doi.org\/10.1136\/jitc-2020-001904.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"7273_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","volume":"20","author":"G Zhu","year":"2021","unstructured":"Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021;20(1):143. https:\/\/doi.org\/10.1186\/s12943-021-01441-4.","journal-title":"Mol Cancer"},{"key":"7273_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2020.02.038","volume":"131","author":"JD Fumet","year":"2020","unstructured":"Fumet JD, Truntzer C, Yarchoan M, Ghiringhelli F. Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts. Eur J Cancer. 2020;131:40\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2020.02.038.","journal-title":"Eur J Cancer"},{"issue":"10","key":"7273_CR28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","volume":"21","author":"J Budczies","year":"2024","unstructured":"Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altb\u00fcrger C, Schwab C, Allg\u00e4uer M, Ahadova A, Kloor M, Schirmacher P, Peters S, Kr\u00e4mer A, Christopoulos P, Stenzinger A. Tumour mutational burden: clinical utility, challenges and emerging improvements. Nat Rev Clin Oncol. 2024;21(10):725\u201342. https:\/\/doi.org\/10.1038\/s41571-024-00932-9.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"7273_CR29","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41467-020-20887-6","volume":"12","author":"PAJ Mendelaar","year":"2021","unstructured":"Mendelaar PAJ, Smid M, van Riet J, Angus L, Labots M, Steeghs N, Hendriks MP, Cirkel GA, van Rooijen JM, Ten Tije AJ, Lolkema MP, Cuppen E, Sleijfer S, Martens JWM, Wilting SM. Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. Nat Commun. 2021;12(1):574. https:\/\/doi.org\/10.1038\/s41467-020-20887-6.","journal-title":"Nat Commun"},{"key":"7273_CR30","doi-asserted-by":"publisher","first-page":"1015308","DOI":"10.3389\/fonc.2022.1015308","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Song J, Liu Z, Zhang T, Liu Y. High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations. Front Oncol. 2022;12:1015308. https:\/\/doi.org\/10.3389\/fonc.2022.1015308.","journal-title":"Front Oncol"},{"issue":"18","key":"7273_CR31","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1158\/1078-0432.CCR-20-0458","volume":"26","author":"A Osipov","year":"2020","unstructured":"Osipov A, Lim SJ, Popovic A, Azad NS, Laheru DA, Zheng L, Jaffee EM, Wang H, Yarchoan M. Tumor mutational Burden, Toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: A Meta-regression analysis. Clin Cancer Res. 2020;26(18):4842\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0458.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7273_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41571-023-00830-6","volume":"21","author":"V Addala","year":"2024","unstructured":"Addala V, Newell F, Pearson JV, Redwood A, Robinson BW, Creaney J, Waddell N. Computational Immunogenomic approaches to predict response to cancer immunotherapies. Nat Rev Clin Oncol. 2024;21(1):28\u201346. https:\/\/doi.org\/10.1038\/s41571-023-00830-6.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"7273_CR33","first-page":"2259","volume":"13","author":"X Huang","year":"2020","unstructured":"Huang X, Cai W, Liu L, Yuan W. Low mutation burden and differential tumor-infiltrating immune cells correlate with lymph node metastasis in colorectal cancer. Int J Clin Exp Pathol. 2020;13(9):2259\u201369.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"7273_CR34","doi-asserted-by":"publisher","first-page":"200786","DOI":"10.1016\/j.omton.2024.200786","volume":"32","author":"E Lou","year":"2024","unstructured":"Lou E, Xiu J, Baca Y, Saeed A, Prakash A, Gholami S, Subramanian S, Starr TK, Fontana E, Pandey R, Lenz HJ, Shields AF, Nabhan C, Oberley M, Seeber A, El-Deiry W. Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers. Mol Ther Oncol. 2024;32(1):200786. https:\/\/doi.org\/10.1016\/j.omton.2024.200786.","journal-title":"Mol Ther Oncol"},{"issue":"2","key":"7273_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/JLB.5AB0220-608R","volume":"108","author":"MA Polidoro","year":"2020","unstructured":"Polidoro MA, Milana F, Soldani C, Franceschini B, Anselmo A, Colombo FS, Di Tommaso L, Cimino M, Carnevale S, Lleo A, Jaillon S, Torzilli G, Donadon M. Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study. J Leukoc Biol. 2020;108(2):715\u201321. https:\/\/doi.org\/10.1002\/JLB.5AB0220-608R.","journal-title":"J Leukoc Biol"},{"key":"7273_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.21037\/tgh-24-28","volume":"9","author":"J Aparicio","year":"2024","unstructured":"Aparicio J. Precision medicine in metastatic colorectal cancer: targeting KRAS G12C mutation. Transl Gastroenterol Hepatol. 2024;9:53. https:\/\/doi.org\/10.21037\/tgh-24-28.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"1","key":"7273_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","volume":"23","author":"MG Fakih","year":"2022","unstructured":"Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022;23(1):115\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(21)00605-7.","journal-title":"Lancet Oncol"},{"issue":"23","key":"7273_CR38","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Saportas Y, Tran Q, Cremolini C, Pietrantonio F, Engl. J Med. 2023;389(23):2125\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2308795.","journal-title":"J Med"},{"issue":"6","key":"7273_CR39","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","volume":"14","author":"R Yaeger","year":"2024","unstructured":"Yaeger R, Uboha NV, Pelster MS, Bekaii-Saab TS, Barve M, Saltzman J, Sabari JK, Peguero JA, Paulson AS, J\u00e4nne PA, Cruz-Correa M, Anderes K, Velastegui K, Yan X, Der-Torossian H, Klempner SJ, Kopetz SE. Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-Mutated metastatic colorectal cancer. Cancer Discov. 2024;14(6):982\u201393. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0217.","journal-title":"Cancer Discov"},{"issue":"10","key":"7273_CR40","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, David Lawson J, Gunn RJ, Smith CR, Thomas NC, Martinson M, Bergstrom A, Sullivan F, Bouhana K, Winski S, He L, Fernandez-Banet J, Pavlicek A, Haling JR, Rahbaek L, Marx MA, Olson P, Christensen JG. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 2022;28(10):2171\u201382. https:\/\/doi.org\/10.1038\/s41591-022-02007-7.","journal-title":"Nat Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07273-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07273-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07273-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:38:16Z","timestamp":1762342696000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07273-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7273"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07273-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Centro AMES under protocol no. CA01\/2024. It was conducted in accordance with the principles of the Declaration of Helsinki and its subsequent amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Monica Ianniello, Raffaella Ruggiero, Roberto Sirica, Nadia Petrillo, Antonio Fico, Luisa Circelli, Antonio Barone, and Giovanni Savarese are employed by AMES, Centro Polidiagnostico Strumentale srl, 80013 Naples, Italy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1226"}}